Moreover, the degree to which UHRF1 loss reverted the increased malignancy upon Rb1 loss suggests that the benefit of UHRF1 targeting could go beyond the scope of osteosarcoma by improving current treatment paradigms of other cancers harboring RB/E2F pathway inactivation. This evidence concerns the gene UHRF1 and cancer.